![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » GENVEC PRESENTS DATA FROM TWO HIV VACCINE STUDIES
GENVEC PRESENTS DATA FROM TWO HIV VACCINE STUDIES
September 1, 2006
GenVec announced results from two Phase I trials at the AIDS Vaccine 2006 Conference in Amsterdam. An HIV vaccine incorporating GenVec's adenovector-based technology was well-tolerated, and results were consistent with previously reported data, including induction of potent immune responses when the vaccine was used alone or in combination with a DNA primer vaccine. The results support the rationale for advanced clinical testing.
In a trial in which the vaccine was given to 40 volunteers as a in one of two dosages, both doses showed stimulation of T-cells against the multiple antigens contained in this vaccine. In a second study, cellular immune responses were analyzed in 14 volunteers given a DNA prime followed by a boost with the HIV vaccine incorporating GenVec's adenovector technology. Data indicate that the combination of priming and boosting produces more polyfunctional T-cells than either modality alone.
"Polyfunctional T-cells are a hallmark of existing vaccines such as the effective smallpox vaccine, and are also believed to be important for an effective HIV vaccine. A similar breadth of polyfunctional T-cells occurs in patients who have HIV but do not progress rapidly to AIDS," said Rick King, GenVec's senior vice president of research.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct